Loading clinical trials...

Host Dendritic Cells in Allograft Patients | Clinical Trials | Clareo Health

UNKNOWNPHASE1

Host Dendritic Cells in Allograft Patients

A Phase I Trial of Host Dendritic Cell Infusion After Allogeneic Stem Cell Transplant for Prevention or for Treatment of Relapsed Disease in Patients With Advanced Hematologic Malignancies

NCT00935597•Icahn School of Medicine at Mount Sinai

View on ClinicalTrials.gov

Summary

The purpose of this study is to assess preliminary efficacy and to determine the safety and feasibility of ex vivo generated dendritic cell (HDC) infusion with and without donor lymphocyte infusion (DLI) after allogeneic stem cell transplant (SCT). We also wish to establish the feasibility of apheresis shipment as well as vaccine shipment and stability in the population.

Eligibility

Age

18 - 70 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Age 18-70
•Ability to sign informed consent
•ECOG performance status ≤3
•Life expectancy \> 6 months
•Adequate cardiac function: MUGA or Echocardiogram demonstrating \>50% Ejection Fraction
•Adequate pulmonary function with DLCO \> 50%
•Adequate hepatic function
•* Bilirubin ≤ 1.5mg/dl
•* Alkaline phosphatase ≤5 times the upper limit of normal
•* Aspartate aminotransferase (AST) or serum glutamic-oxaloacetic transferase (SGOT) ≤ 3 times the upper limit of normal
+11 more criteria

Exclusion Criteria

•Malignancies other than melanoma within five years of study entry, except carcinoma in-situ of the cervix or basal/squamous cell skin cancers
•Concurrent illnesses that would preclude survival \> 6 months other than the disease under study
•Pregnancy or nursing
•HIV infection
•Treatment with prior donor lymphocyte infusion
•Prior allogeneic stem cell transplant
•History of autoimmune diseases including systemic lupus erythematosus, rheumatoid arthritis and thyroiditis
•Active infections including fungal infections and viral hepatitis
•GVHD greater than grade I GVHD of the skin
•Malignancies other than melanoma within five years of study entry, except carcinoma in-situ of the cervix or basal/squamous cell skin cancers
+11 more criteria

Locations (1)

Mount Sinai Medical Center

New York, New York, United States

Key Dates

Start Date

August 1, 2009

Primary Completion Date

July 1, 2013

Last Updated

October 29, 2010

Enrollment

ESTIMATED participants

Conditions

Relapsed Non-Hodgkin's LymphomaHodgkin's DiseaseMultiple MyelomaChronic Lymphocytic Lymphoma

Interventions

MSSM/BIIR HDC Vax-001 (Host Dendritic Cells)

BIOLOGICAL

Contacts

Keren Osman, MD

CONTACT

(212)241-6021 keren.osman@mssm.edu

Linda Sacris, RN

CONTACT

(212)824-7339 linda.sacris@mssm.edu

Iberdomide Versus Observation Off Therapy After Idecabtagene Vicleucel CAR-T for Multiple Myeloma

NCT06179888

Multiple Myeloma

View study

RECRUITINGPHASE3

MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)

NCT06152575

Multiple Myeloma

View study

RECRUITINGPHASE1/PHASE2

A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: October 29, 2010Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Host Dendritic Cells in Allograft Patients

Inclusion Criteria

Exclusion Criteria

Iberdomide Versus Observation Off Therapy After Idecabtagene Vicleucel CAR-T for Multiple Myeloma

MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)

A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma

A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel

Elranatamab in R/R Multiple Myeloma

Study of ISB 2001 in Relapsed/Refractory Multiple Myeloma (TRIgnite-1)